Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual

Commonly-used Abbreviations 1

Oral Presentations

Experience in the Implementation of Long-Acting Treatment 3

Antiretroviral Treatment Strategies 5

Infection Prevention 6

Integrase Strand Transfer Inhibitor (INSTI) Resistance 7

Co-morbidities and Co-infections 9

PrEP-ing for the Future 17

Poster Presentations

ARV-based prevention—Vertical transmission 20

ARV-based prevention—PEP 28

ARV-based prevention—PrEP 29

Treatment strategies—Novel therapeutic targets (phase I and II) 45

Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47

Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66

Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122

Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147

Treatment strategies—Rapid ART initiation 149

Treatment strategies—Adherence 158

Clinical management considerations—Women 164

Clinical management considerations—Late presenters 170

Clinical management considerations—People who inject drugs (PWID) 180

Clinical management considerations—Transgender people 181

Clinical management considerations—Adolescents 182

Clinical management considerations—Paediatrics 183

Clinical management considerations—Drug-drug interactions 187

Cure/post-treatment control 194

Opportunistic infections and AIDS-defining cancers 200

Clinical pharmacology 206

Community-based treatment and prevention initiatives, including primary care screening 209

Public health strategies including of policy options 219

Cost and cost-effectiveness 233

Models of care: evaluation of ARV delivery and coverage 237

Co-morbidities and complications of disease and/or treatment—Ageing and frailty 245

Co-morbidities and complications of disease and/or treatment—Cardiovascular/metabolic including weight gain 249

Co-morbidities and complications of disease and/or treatment—Malignancies: non-AIDS defining 273

Co-morbidities and complications of disease and/or treatment—Neurological 280

Co-morbidities and complications of disease and/or treatment—Renal 282

Co-morbidities and complications of disease and/or treatment—Mental health disorders 287

Co-morbidities and complications of disease and/or treatment—Other 291

People living with HIV and COVID-19: Outcomes 304

People living with HIV and mpox virus 307

People living with HIV and sexually transmitted diseases 311

People living with HIV and tuberculosis 320

People living with HIV and viral hepatitis 323

People living with HIV and other diseases 329

Author Index 335